8 documents

Read All
16:40 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data at...
Read More
22:32 , Jan 23, 2018 |  BC Extra  |  Clinical News

ChemoCentryx reports OS data for CCR2 antagonist in pancreatic cancer

ChemoCentryx Inc. (NASDAQ:CCXI) said CCX872 plus FOLFIRINOX chemotherapy led to an 18-month overall survival rate of 29% in a Phase Ib trial to treat advanced non-resectable pancreatic cancer. The company will present the data on...
Read More
20:58 , Dec 19, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; lung cancer Mouse studies suggest inhibiting CCR2 in combination with radiotherapy could help treat colon and lung cancers. In mouse models of colon and lung cancers, systemic knockout of CCR2 plus radiation decreased...
Read More
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

CCX872: Phase Ib data

Top-line data from 41 evaluable patients with non-resectable pancreatic cancer who had >=1 post-baseline CT scan in an open-label, U.S. and Dutch Phase Ib trial showed that twice-daily 150 mg oral CCX872 plus FOLFIRINOX chemotherapy...
Read More
07:00 , May 4, 2015 |  BC Week In Review  |  Clinical News

CCX872: Phase Ib started

ChemoCentryx began an open-label Phase Ib trial to evaluate 150 mg oral CCX872 twice daily plus FOLFIRINOX chemotherapy for >=12 weeks in up to 54 patients. ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif.   Product: CCX872...
Read More
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CC chemokine receptor 2 (CCR2; CD192)

Inflammation INDICATION: Shock / trauma Mouse studies suggest CCR2 antagonists could help treat traumatic brain injury (TBI). In a mouse model of TBI, peripherally derived CCR2-expressing macrophages accumulated in the hippocampus and their accumulation was associated with...
Read More
08:00 , Dec 10, 2012 |  BC Week In Review  |  Clinical News

CCX872: Phase I started

ChemoCentryx began a double-blind, placebo-controlled Phase I trial of single and multiple ascending-doses of oral CCX872 in 40 healthy volunteers. ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif.   Product: CCX872   Business: Endocrine/Metabolic   Molecular target: CC chemokine...
Read More
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

ChemoCentryx preclinical data

In a genetic mouse model of diabetic nephropathy, CCX872 produced a "pronounced improvement" in albuminuria and histological measures of kidney damage, such as glomerular basement membrane thickening. Data were presented at the European Association for...
Read More